Modality
Gene Therapy
MOA
CGRPant
Target
PD-1
Pathway
Angiogenesis
MGMM
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
Jul 2019
→ Aug 2026
Phase 1Current
NCT04431867
261 pts·MM
2019-07→2026-08·Active
261 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-094mo awayInterim· MM
2026-10-267mo awayConference· MM
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Active
Catalysts
Interim
2026-08-09 · 4mo away
MM
Conference
2026-10-26 · 7mo away
MM
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04431867 | Phase 1 | MM | Active | 261 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| INC-2432 | Incyte | Phase 2 | CD47 |